Literature DB >> 23295694

Clinical risk factors for complicated disease: how reliable are they?

Camille Zallot1, Laurent Peyrin-Biroulet.   

Abstract

Crohn's disease is a chronic, progressive, destructive disease. Complicated disease can be defined as the presence of bowel damage (stricture, abscess or fistula) and/or the need for surgery. Natural history studies provide invaluable data on the disease course. In population-based cohorts, half of all patients experienced an intestinal complication within 20 years after diagnosis and half of the patients required surgery within 10 years after diagnosis. In Olmsted County, the factors associated with the development of complications were the presence of ileal involvement and perianal disease. The extent of noncolonic disease, current smoking, male gender, penetrating disease behavior and early steroid use were significantly associated with major abdominal surgery. Overall, using various definitions of complicated disease, the predictors of a worse outcome in Crohn's disease were: extensive small bowel disease, severe upper gastrointestinal disease, rectal disease, perianal lesions, early stricturing/penetrating disease, smoking and a young age at diagnosis. Aggressive ulcerative colitis was recently defined as a disease that is associated with a high relapse rate, the need for surgery, the development of colon cancer or the presence of extraintestinal manifestations. About one tenth of patients still require colectomy for ulcerative colitis at 5 years in the era of biologics. An average of 1.6% of patients with ulcerative colitis was diagnosed with colorectal cancer during 14 years of follow-up in population-based cohorts. A younger age at diagnosis and pancolitis were associated with a worse outcome in ulcerative colitis. The identification of clinical risk factors for complicated disease may be used in future disease-modification trials.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 23295694     DOI: 10.1159/000342608

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  19 in total

Review 1.  The Role of Early Biologic Therapy in Inflammatory Bowel Disease.

Authors:  Dana Rachel Berg; Jean-Frederic Colombel; Ryan Ungaro
Journal:  Inflamm Bowel Dis       Date:  2019-11-14       Impact factor: 5.325

2.  NOD2 gene mutations in ulcerative colitis: useless or misunderstood?

Authors:  Paulo Freire; Ricardo Cardoso; Pedro Figueiredo; Maria M Donato; Manuela Ferreira; Sofia Mendes; Ana Margarida Ferreira; Helena Vasconcelos; Francisco Portela; Carlos Sofia
Journal:  Int J Colorectal Dis       Date:  2014-03-22       Impact factor: 2.571

3.  Improvements in the Long-Term Outcome of Crohn's Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort.

Authors:  Steven F G Jeuring; Tim R A van den Heuvel; Limmie Y L Liu; Maurice P Zeegers; Wim H Hameeteman; Mariëlle J L Romberg-Camps; Liekele E Oostenbrug; Ad A M Masclee; Daisy M A E Jonkers; Marieke J Pierik
Journal:  Am J Gastroenterol       Date:  2016-12-06       Impact factor: 10.864

Review 4.  Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease.

Authors:  K T Park; Wallace V Crandall; Jacqueline Fridge; Ian H Leibowitz; Marc Tsou; Dana M H Dykes; Edward J Hoffenberg; Michael D Kappelman; Richard B Colletti
Journal:  Inflamm Bowel Dis       Date:  2014-05       Impact factor: 5.325

Review 5.  Inflammatory bowel disease surgery in the biologic era.

Authors:  Linda Ferrari; Mukta K Krane; Alessandro Fichera
Journal:  World J Gastrointest Surg       Date:  2016-05-27

Review 6.  Long-term safety of immunomodulators in pediatric inflammatory diseases.

Authors:  Federica Nuti; Fortunata Civitelli; Salvatore Cucchiara
Journal:  Paediatr Drugs       Date:  2014-10       Impact factor: 3.022

7.  Creeping Fat Assessed by Small Bowel MRI Is Linked to Bowel Damage and Abdominal Surgery in Crohn's Disease.

Authors:  Patrick Althoff; Wolff Schmiegel; Gernot Lang; Volkmar Nicolas; Thorsten Brechmann
Journal:  Dig Dis Sci       Date:  2018-10-01       Impact factor: 3.199

Review 8.  First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?

Authors:  Laurent Peyrin-Biroulet; Gionata Fiorino; Anthony Buisson; Silvio Danese
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

9.  Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging.

Authors:  Uri Kopylov; Doron Yablecovitch; Adi Lahat; Sandra Neuman; Nina Levhar; Tomer Greener; Eyal Klang; Noa Rozendorn; Marianne M Amitai; Shomron Ben-Horin; Rami Eliakim
Journal:  Am J Gastroenterol       Date:  2015-07-28       Impact factor: 10.864

Review 10.  Management of Crohn Disease: A Review.

Authors:  Kelly Cushing; Peter D R Higgins
Journal:  JAMA       Date:  2021-01-05       Impact factor: 157.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.